Allergan win round in Patent Battle

As reported by Reuters, speciality pharmaceutical Allergan Inc are locked in a patent battle over their glaucoma drug Lumen.

Pharmaceutical jobsFighting against two generic drug makers, they found out on Monday that they had won the first round when the U.S. Court of Appeals for the Federal Circuit ruled that it would be an infringement of the patent if they went through with plans to sell a generic version of Lumigan.

Best known for their anti-wrinkle treatment, Botox, Allergan also  has one of the biggest arrays of prescription eye medicines in the industry with  Lumigan alone making annual sales of more than $600 million.

Click here to see our latest pharmaceutical jobs

Posted in: News
CK Logo in place of featured image